A new gene therapy approach for treating atrial fibrillation
A New and Disruptive Gene Based Therapy for Atrial Fibrillation
This study is testing a new gene therapy that aims to help people with atrial fibrillation, a common heart rhythm problem, by delivering special genetic material directly to the heart to improve treatment results.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inomagen Therapeutics, INC NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10563221 on NIH RePORTER |
What this research studies
This research focuses on developing a novel gene therapy to treat atrial fibrillation (AF), a common heart rhythm disorder affecting millions. The approach targets the underlying molecular mechanisms that contribute to AF, specifically oxidative injury, which is believed to play a significant role in the condition. By using a specialized catheter and electroporation, the therapy aims to deliver genetic material directly to the heart tissue, potentially improving treatment outcomes for patients with persistent AF. This innovative method seeks to provide a more effective solution compared to existing pharmacological and ablation therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with persistent atrial fibrillation, particularly those who have not responded well to current treatment options.
Not a fit: Patients with atrial fibrillation who are not persistent or those who have contraindications to gene therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for atrial fibrillation, reducing the risk of stroke and improving quality of life for patients.
How similar studies have performed: While gene therapy for heart conditions is an emerging field, this specific approach targeting atrial fibrillation is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Chicago, United States
- Inomagen Therapeutics, INC — Chicago, United States (Active)
Researchers
- Principal investigator: Moen, Robert Charles — Inomagen Therapeutics, INC
- Study coordinator: Moen, Robert Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.